Clinical trial evidence indicates that the blockade of the RAS by ACE inhibitors or AT1 receptor blockers (ARB) has been shown to alleviate renal injury, improve renal function and reduce renal events in patients with chronic kidney diseases and ESRD [2, 5, 6, 29, 34]. This evidence concerns the gene AGTR1 and chronic kidney disease.